Opko Health
Open
$1.40
Prev. Close
$1.40
High
$1.40
Low
$1.39
Market Snapshot
$1.07B
-5.0
-0.07
$713.14M
OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. The company is headquartered in Miami, Florida and currently employs 2,275 full-time employees. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.
Opko Health reports promising preclinical results for OPK8801001, suggesting potential undervaluation and increased investor interest in the company's future prospects.
OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. The company is headquartered in Miami, Florida and currently employs 2,275 full-time employees. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.
Recently from Cashu
OPKO Health Expands Partnership with Nicoya to Enhance RAYALDEE Commercialization in China
OPKO Health (Ticker: OPK) reinforces its strategic partnership with Nicoya Therapeutics to enhance the commercialization of RAYALDEE, a pharmaceutical product aimed at addressing renal health needs in…
Opko Health's Q4 Earnings Highlight Commitment to Innovative Healthcare Despite Market Challenges
Opko Health's Q4 Earnings Reveal Commitment to Innovative Healthcare Solutions Opko Health, a prominent player in the healthcare sector, reports its Q4 earnings during a conference call held on Februa…
OPKO Health's Innovations Enhance Performance Amid Ongoing Market Challenges and Growth Potential
Transformative Innovations Drive OPKO Health’s Performance Amid Market Challenges OPKO Health achieves a noteworthy milestone with its recent quarterly earnings report, demonstrating resilience and po…
Opko Health Reports 15% Revenue Growth, Demonstrates Strategic Resilience Amidst Industry Challenges
Opko Health's Strategic Growth Amidst Industry Challenges Opko Health continues to solidify its position in the healthcare sector with its latest financial results, showcasing a robust performance tha…